|1.||Müller, W: 17 articles (10/2006 - 01/2000)|
|2.||Stratz, T: 14 articles (10/2006 - 01/2000)|
|3.||Navari, Rudolph M: 8 articles (10/2015 - 07/2003)|
|4.||Trissel, Lawrence A: 6 articles (01/2009 - 02/2005)|
|5.||Trusley, Craig: 5 articles (01/2009 - 11/2007)|
|6.||Kupiec, Thomas C: 5 articles (01/2009 - 11/2007)|
|7.||Späth, M: 5 articles (01/2004 - 01/2000)|
|8.||Mousavizadeh, Kazem: 4 articles (12/2015 - 06/2008)|
|9.||Cox, David: 4 articles (07/2014 - 08/2011)|
|10.||Rudd, John A: 4 articles (03/2014 - 07/2003)|
08/01/2014 - "Acute emesis has largely been alleviated with the use of 5-HT3 receptor antagonists, while an improvement in preventing delayed emesis has been achieved with NK1 receptor antagonists. "
11/01/1995 - "However, with the development of basic research on the mechanisms of vomiting, each 5-HT3 receptor antagonist has appeared to have different pharmacological actions and, subsequently, the difference in the clinical efficacy of each drug has been reported in Europe and USA. "
07/01/2000 - "Studies have yielded conflicting results concerning the use of 5-HT3 receptor antagonists alone in delayed emesis. "
06/01/1996 - "Further studies in animals have provided valuable information relating to the pathophysiology of emesis and the mechanism of action of 5-HT3 receptor antagonists. "
02/01/1990 - "In view of the widespread use of the ferret in studies of emesis and particularly in the characterization of the antiemetic actions of 5-HT3 receptor antagonist, the opportunity is taken to assess the suitability of this species for studies of emesis. "
07/01/2000 - "The enhancement of NK1 receptor antagonist antiemetic activity through combination with a 5-HT3 receptor antagonist is not replicated in motion-induced nausea."
02/01/1996 - "Several basics are investigated and depending on this knowledge some special treatment strategies have been developed (5-HT3-receptor-antagonists in the treatment of nausea, Figure 1, Table 2). "
07/01/1999 - "The 5-HT3 receptor antagonists are the most effective agents against chemotherapy-induced nausea and should become standard antiemetic therapy for high-risk patients. "
05/15/2003 - "The 5-HT3 receptor antagonists are effective for preventing nausea and vomiting from these causes. "
06/01/2011 - "The 5-HT3 receptor is one of a number of receptors that play a role in mediating nausea and vomiting, and as such, 5-HT3 receptor antagonists demonstrate the greatest anti-emetic efficacy when administered in combination with other drug classes."
|3.||Postoperative Nausea and Vomiting (PONV)
01/01/2007 - "The purpose of this meta-analysis was to assess the efficacy of prophylactic administration of 5-HT3 receptor antagonists for postoperative nausea and vomiting in neurosurgical patients at 24 and 48+ hours. "
01/01/2007 - "Despite the ability of 5-HT3 receptor antagonists to reduce emetic episodes, future investigations should seek to address the control of postoperative nausea and to reduce further postoperative emesis in this population."
06/01/2006 - "A brief overview of the incidence, risk factors and current management recommendations for PONV and current controversies with special emphasis on the 5-HT3 receptor antagonists, is discussed."
01/01/2006 - "The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting."
02/01/2003 - "We conclude that the risk of postoperative nausea and vomiting remained high in this setting despite 5-HT3 receptor antagonist prophylaxis and that the choice between these agents should be based on the lowest available acquisition cost."
04/01/2015 - "Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter."
05/01/1998 - "Antiemetic efficacy of subcutaneous 5-HT3 receptor antagonists in terminal cancer patients."
10/15/2006 - "The objective of this study is to evaluate the ECG changes after administration of 5-HT3 receptor antagonists and chemotherapeutic agents in children with cancer. "
09/01/2005 - "However, due to patient exclusion criteria, such trials with 5-HT3 receptor antagonists may have failed to examine the risk of these agents in "real world" patients with cancer. "
08/01/2004 - "Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients."
09/24/2015 - "Spinal 5-HT3 receptor (5-HT3R) has been implicated in chronic pain development. "
01/01/2014 - "However, the mechanisms underlying the activation of the 5-HT3 receptor and its contribution to facilitation of pain remain unclear. "
02/01/2007 - "[Antinociceptive properties of the 5-HT3 receptor antagonist in the model of inflammatory pain in rats of different age with prenatal deficit of serotonine and under stress]."
12/22/2000 - "The 5-HT3 receptor may therefore be involved in the mediation of TMJ pain in systemic inflammatory joint disorders."
12/01/1996 - "This distribution implies that some 5-HT3 receptor antagonists might reduce certain symptoms of IBS, such as pain, by reducing the reactivity of the visceral afferent neurones linking the gut with the brain and spinal cord. "
|7.||Serotonin (5 Hydroxytryptamine)
|1.||Drug Therapy (Chemotherapy)
|5.||Fluid Therapy (Oral Rehydration Therapy)